OpSens will Participate at Stifel 2021 Virtual Healthcare Conference and Canaccord Genuity MedTech & Diagnostics Forum

QUEBEC CITY, Nov. 10, 2021 /CNW/ - OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company commercializing a second-generation fiber optic pressure guidewire to diagnose and treat coronary artery disease, announced today that Louis Laflamme, President and Chief Executive Officer will participate at the two following investment conferences:

• Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021

The OpSens presentation will be at 3:20 PM ET on November 17, 2021. The webcast of the presentation will be available at https://wsw.com/webcast/stifel58/ops.to/2389500, or through the OpSens investor page at www.OpSens.com.

Management will participate in virtual one-on-one meetings throughout the day.

• Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 18, 2021

Management is scheduled to host virtual one-on-one meetings throughout the day.

About OpSens Inc. (www.OpSens.com or OpSensMedical.com)
OpSens focuses mainly on products for cardiology. OpSens offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 150,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

SOURCE OPSENS Inc.